Nalador (Sulprostone)

Sulprostone mimics prostaglandin E2 and activates EP receptors on smooth‑muscle and gastric cells. This activation leads to stronger uterine contractions and enhanced secretion of gastric mucus and bicarbonate, providing both uterotonic and gastroprotective actions.

The specific dose of Nalador is determined by the prescribing clinician based on the indication, patient condition, and clinical response. Healthcare professionals adjust the regimen to achieve the desired therapeutic effect while monitoring safety.

Nalador is used during labor to facilitate delivery, so it is administered to pregnant women under medical supervision. Its safety profile for breastfeeding is not well defined; clinicians weigh potential benefits against risks before use.

To order Nalador, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and required import documentation.

The main alternatives for uterine stimulation are oxytocin and misoprostol. Compared with oxytocin, sulprostone has a direct prostaglandin‑mediated mechanism and may produce stronger uterine contractions. Compared with misoprostol, sulprostone is administered intravenously, allowing rapid titration, whereas misoprostol is given orally or vaginally.

Nalador must be stored at 2‑8 °C in a refrigerator, protected from light. The vial should remain in its original packaging, must not be frozen, and should be gently inverted if mixing is required. Once removed from refrigeration, use within the time frame specified by the manufacturer.

Nalador is supplied as a sterile injectable solution for intravenous (IV) administration. The medication is drawn into a syringe and infused slowly under continuous clinical observation, allowing the prescriber to adjust the rate based on uterine response or gastric protection needs.

Serious risks include uterine hyperstimulation that can cause fetal distress, severe hypotension, and rare but life‑threatening allergic reactions such as anaphylaxis. Prompt recognition and immediate medical intervention are essential if any of these events occur.

Nalador should be avoided in patients with known hypersensitivity to sulprostone or other prostaglandin analogs, in those with uncontrolled cardiovascular disease, severe asthma, or conditions where excessive uterine contraction could be harmful. Contra‑indications are determined by the treating physician.